First Quarter Sales to HUT Group Doubled Over 2014

Fort Lee, New Jersey, USA, March 27, 2015 (GLOBE NEWSWIRE) -- Herborium® Group, Inc. (OTC Pink: HBRM),, a Botanical Therapeutics® Company and the provider of unique all botanical medicines (Botanical Therapeutics®) announced today that its sales to HUT Group, LLC. , the UK's leading multi-website online retailer of Health and Beauty products has doubled over the same period of 2014.

As agreed to in the revised Agreement in December 2014 HUT has successfully increased its marketing and sales of AcnEase®, Herborium's unique acne treatment, on its multiple highly ranked e- commerce platforms, and therefore keept the sale projection on track for reaching $500,000 sales in Europe within 18-24 months.

The HUT Group is one of Europe's fastest growing online lifestyle and health & and beauty destinations. It is currently the UK's leading multi-website online retailer with rapidly growing global operations including a significant growth in Asia. Hut supports more than 140 million global website visitors, 5 million customers and 8 million orders dispatched worldwide across such on line stores as,,,, and others.

"We are very excited about the present growth in sales of AcnEase® on HUT's unique "end to end" technology platform. With potential for a million page views daily our Botanical Therapeutics® will reach millions of customers in Europe and Asia. We are expecting HUT goal for $500,000 in sales of AcnEase® to be just a beginning of Herborium's new growth opportunities in Europe that are also strongly supported by the continuous growth of our French market sales. France is the 4th largest world market for beauty and skincare related products. " commented Dr. Agnes P. Olszewski, CEO and Chairwoman of Herborium.

About Herborium Group, Inc.

Herborium Group, Inc., a botanical therapeutics® company that develops, license and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, wellness and energy, prostate health, women's health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, diabetes, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. For more information, please visit, and

Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Herborium Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.

CONTACT: Herborium Group, Inc. Email:

Source:Herborium Group, Inc.